An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

New York, New York-- (Newsfile Corp. - January 22, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

Alphabet Inc.’s Google has deepened its commitment to artificial intelligence (AI) by investing an additional $1 billion in ...

New York, New York-- (Newsfile Corp. - January 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this ...

The global vaccine storage equipment market, valued at US$0.82 billion in 2023, is forecasted to grow at a robust CAGR of 7.2%, reaching US$0.86 billion in 2024 and an impressive US$1.21 billion by ...

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of ...

European banks are on the up and up. And President Donald Trump has thrown spikes on the road for US climate policy. Plus, mining companies in Africa’s Sahel region are being targeted. Aanu Adeoye ...